Tufts University School of Medicine, Division of Hematology/Oncology, Department of Medicine, Director, GI Oncology Program 800 Washington Street, Box 245, Boston, MA 02111, USA.
Anticancer Res. 2013 May;33(5):2175-7.
Advanced pancreatic neuroendocrine tumor (PNET) presents a therapeutic challenge as many are unresectable and relatively resistant to systemic therapy with a high malignant potential. We share our experience using concurrent capecitabine or infusional 5-fluorouracil with radiation for patients with resected and locally advanced PNET.
Six patients (two females, four males) with PNET were treated with capecitabine or infusional 5-FU and concurrent radiation.
The median age was 52 years (range: 38 to 63 years), with ECOG Performance Status (PS) 0-1, grade 0-1 weight loss, and grade 0-1 pain. One patient underwent resection with negative margins, two with positive margins, and three had unresectable locally advanced disease. All six patients demonstrated partial radiographic response and sustained local control. The treatment was tolerable with only grade 2 hand-foot syndrome and grade 1 mucositis observed.
Prospective studies to further investigate the role of chemoradiation in this setting are warranted.
晚期胰腺神经内分泌肿瘤（PNET）的治疗极具挑战性，因为许多肿瘤无法切除，且对全身治疗具有相对耐药性，恶性程度较高。我们分享了使用卡培他滨或氟尿嘧啶持续输注联合放疗治疗可切除和局部进展性 PNET 患者的经验。
6 例 PNET 患者（2 名女性，4 名男性）接受卡培他滨或氟尿嘧啶持续输注联合放疗。
中位年龄为 52 岁（范围：38 至 63 岁），ECOG 表现状态（PS）0-1 分，体重减轻 0-1 级，疼痛 0-1 级。1 例患者接受了无肿瘤边缘残留的切除术，2 例患者有肿瘤边缘残留，3 例患者患有无法切除的局部进展性疾病。所有 6 例患者均显示部分影像学反应和持续的局部控制。治疗耐受性良好，仅观察到 2 级手足综合征和 1 级黏膜炎。
有必要开展前瞻性研究，进一步探讨该治疗方案在这种情况下的作用。
